{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:47:38Z","timestamp":1793296058585,"version":"4.5.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31801121"],"award-info":[{"award-number":["31801121"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFA1301200"],"award-info":[{"award-number":["2021YFA1301200"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.biopha.2022.113787","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T06:31:07Z","timestamp":1665037867000},"page":"113787","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Patterns of immune infiltration and survival in endocrine therapy-treated ER-positive breast cancer: A computational study of 1900 patients"],"prefix":"10.1016","volume":"155","author":[{"given":"Wei-Quan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Hao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biopha.2022.113787_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: Cancer J. Clin."},{"issue":"9","key":"10.1016\/j.biopha.2022.113787_bib2","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1002\/ijc.28222","article-title":"Divergent estrogen receptor-positive and -negative breast cancer trends and etiologic heterogeneity in Denmark","volume":"133","author":"Anderson","year":"2013","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2022.113787_bib3","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/s41416-020-0938-z","article-title":"Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: a population-based study of Scottish cancer registry data","volume":"123","author":"Mesa-Eguiagaray","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"5.5","key":"10.1016\/j.biopha.2022.113787_bib4","first-page":"552","article-title":"NCCN guidelines updates: breast cancer","volume":"17","author":"Telli","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"19","key":"10.1016\/j.biopha.2022.113787_bib5","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years","volume":"377","author":"Pan","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.biopha.2022.113787_bib6","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ccell.2020.03.009","article-title":"Overcoming endocrine resistance in breast cancer","volume":"37","author":"Hanker","year":"2020","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.biopha.2022.113787_bib7","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1172\/JCI41680","article-title":"Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer","volume":"120","author":"Miller","year":"2010","journal-title":"J. Clin. Investig."},{"issue":"3","key":"10.1016\/j.biopha.2022.113787_bib8","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccell.2018.08.008","article-title":"The genomic landscape of endocrine-resistant advanced breast cancers","volume":"34","author":"Razavi","year":"2018","journal-title":"Cancer Cell"},{"issue":"22","key":"10.1016\/j.biopha.2022.113787_bib9","doi-asserted-by":"crossref","first-page":"E4482","DOI":"10.1073\/pnas.1620993114","article-title":"Embryonic transcription factor SOX9 drives breast cancer endocrine resistance","volume":"114","author":"Jeselsohn","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.biopha.2022.113787_bib10","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.celrep.2018.07.009","article-title":"Functional annotation of ESR1 gene fusions in estrogen receptor-positive breast cancer","volume":"24","author":"Lei","year":"2018","journal-title":"Cell Rep."},{"issue":"4","key":"10.1016\/j.biopha.2022.113787_bib11","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1158\/0008-5472.CAN-09-3292","article-title":"Antiestrogens induce transforming growth factor beta-mediated immunosuppression in breast cancer","volume":"70","author":"Joffroy","year":"2010","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.biopha.2022.113787_bib12","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/jnci\/djz213","article-title":"Immune checkpoint profiles in luminal B breast cancer (alliance)","volume":"112","author":"Anurag","year":"2020","journal-title":"Jnci-J. Natl. Cancer Inst."},{"key":"10.1016\/j.biopha.2022.113787_bib13","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.canlet.2019.11.009","article-title":"Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy","volume":"470","author":"Lei","year":"2020","journal-title":"Cancer Lett."},{"issue":"7637","key":"10.1016\/j.biopha.2022.113787_bib14","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"issue":"27","key":"10.1016\/j.biopha.2022.113787_bib15","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1200\/JCO.2013.55.0491","article-title":"Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199","volume":"32","author":"Adams","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.biopha.2022.113787_bib16","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/annonc\/mdu191","article-title":"Association between CD8+T-cell infiltration and breast cancer survival in 12,439 patients","volume":"25","author":"Ali","year":"2014","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.biopha.2022.113787_bib17","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1200\/JCO.2014.58.1967","article-title":"Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers","volume":"33","author":"Denkert","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.biopha.2022.113787_bib18","doi-asserted-by":"crossref","first-page":"5747","DOI":"10.1158\/1078-0432.CCR-15-2338","article-title":"Tumor-infiltrating lymphocytes: a predictive and prognostic biomarker in neoadjuvant-treated HER2-positive breast cancer","volume":"22","author":"Ingold Heppner","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2022.113787_bib19","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1371\/journal.pmed.1002194","article-title":"Patterns of immune infiltration in breast cancer and their clinical implications: a gene-expression-based retrospective study","volume":"13","author":"Ali","year":"2016","journal-title":"PLoS Med."},{"issue":"7","key":"10.1016\/j.biopha.2022.113787_bib20","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1200\/JCO.2011.41.0902","article-title":"Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98","volume":"31","author":"Loi","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2022.113787_bib21","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13058-020-01364-w","article-title":"Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up","volume":"22","author":"Lundgren","year":"2020","journal-title":"Breast Cancer Res."},{"issue":"7","key":"10.1016\/j.biopha.2022.113787_bib22","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","article-title":"Determining cell type abundance and expression from bulk tissues with digital cytometry","volume":"37","author":"Newman","year":"2019","journal-title":"Nat. Biotechnol."},{"issue":"10","key":"10.1016\/j.biopha.2022.113787_bib23","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2006.07.1522","article-title":"Definition of clinically distinct molecular subtypes in estrogen receptor\u2013positive breast carcinomas through genomic grade","volume":"25","author":"Loi","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2022.113787_bib24","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2164-9-239","article-title":"Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen","volume":"9","author":"Loi","year":"2008","journal-title":"BMC Genom."},{"issue":"27","key":"10.1016\/j.biopha.2022.113787_bib25","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1200\/JCO.2010.28.4273","article-title":"Genomic index of sensitivity to endocrine therapy for breast cancer","volume":"28","author":"Symmans","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2022.113787_bib26","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10549-008-0183-2","article-title":"The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy","volume":"116","author":"Zhang","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.biopha.2022.113787_bib27","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1755-8794-2-40","article-title":"The Gene Expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial","volume":"2","author":"Desmedt","year":"2009","journal-title":"BMC Med. Genom."},{"issue":"4","key":"10.1016\/j.biopha.2022.113787_bib28","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gng015","article-title":"Summaries of Affymetrix GeneChip probe level data","volume":"31","author":"Irizarry","year":"2003","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.biopha.2022.113787_bib29","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/1471-2105-12-322","article-title":"Strategies for aggregating gene expression data: the collapseRows R function","volume":"12","author":"Miller","year":"2011","journal-title":"BMC Bioinform."},{"issue":"6797","key":"10.1016\/j.biopha.2022.113787_bib30","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.biopha.2022.113787_bib31","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","article-title":"Supervised risk predictor of breast cancer based on intrinsic subtypes","volume":"27","author":"Parker","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2022.113787_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v033.i01","article-title":"Regularization paths for generalized linear models via coordinate descent","volume":"33","author":"Friedman","year":"2010","journal-title":"J. Stat. Softw."},{"key":"10.1016\/j.biopha.2022.113787_bib33","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2022.113787_bib34","unstructured":"R Core Team, R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing, 2021; Available from: \u3008https:\/\/www.R-project.org\/\u3009, (In:)."},{"key":"10.1016\/j.biopha.2022.113787_bib35","first-page":"9","article-title":"Six novel immunoglobulin genes as biomarkers for better prognosis in triple-negative breast cancer by gene co-expression network analysis","author":"Hsu","year":"2019","journal-title":"Sci. Rep."},{"issue":"21","key":"10.1016\/j.biopha.2022.113787_bib36","doi-asserted-by":"crossref","first-page":"9328","DOI":"10.18632\/aging.102373","article-title":"Bioinformatic profiling of prognosis-related genes in the breast cancer immune microenvironment","volume":"11","author":"Bai","year":"2019","journal-title":"Aging"},{"issue":"12","key":"10.1016\/j.biopha.2022.113787_bib37","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1111\/jcmm.13882","article-title":"STAT1 facilitates oestrogen receptor alpha transcription and stimulates breast cancer cell proliferation","volume":"22","author":"Hou","year":"2018","journal-title":"J. Cell. Mol. Med."},{"issue":"17","key":"10.1016\/j.biopha.2022.113787_bib38","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.7150\/ijms.43161","article-title":"HCK can serve as novel prognostic biomarker and therapeutic target for breast cancer patients","volume":"17","author":"Zhu","year":"2020","journal-title":"Int. J. Med. Sci."},{"issue":"7","key":"10.1016\/j.biopha.2022.113787_bib39","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nrc.2016.52","article-title":"Neutrophils in cancer: neutral no more","volume":"16","author":"Coffelt","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.biopha.2022.113787_bib40","first-page":"2194","article-title":"Recruitment of monocytes and epigenetic silencing of intratumoral CYP7B1 primarily contribute to the accumulation of 27-hydroxycholesterol in breast cancer","volume":"9","author":"Shi","year":"2019","journal-title":"Am. J. Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2022.113787_bib41","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1146\/annurev-immunol-042718-041717","article-title":"Regulatory T cells and human disease","volume":"38","author":"Sakaguchi","year":"2020","journal-title":"Annu. Rev. Immunol."},{"issue":"34","key":"10.1016\/j.biopha.2022.113787_bib42","doi-asserted-by":"crossref","first-page":"5373","DOI":"10.1200\/JCO.2006.05.9584","article-title":"Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse","volume":"24","author":"Bates","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"7900","key":"10.1016\/j.biopha.2022.113787_bib43","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/s41586-022-04439-0","article-title":"A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells","volume":"603","author":"Seung","year":"2022","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.biopha.2022.113787_bib44","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/modpathol.3800094","article-title":"The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis","volume":"17","author":"Dabiri","year":"2004","journal-title":"Mod. Pathol."},{"issue":"1","key":"10.1016\/j.biopha.2022.113787_bib45","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3892\/ijo_00000319","article-title":"Tryptase-positive mast cells correlate with angiogenesis in early breast cancer patients","volume":"35","author":"Ranieri","year":"2009","journal-title":"Int. J. Oncol."},{"issue":"32","key":"10.1016\/j.biopha.2022.113787_bib46","doi-asserted-by":"crossref","first-page":"22727","DOI":"10.18632\/oncotarget.25220","article-title":"Bcl6\/p53 expression, macrophages\/mast cells infiltration and microvascular density in invasive breast carcinoma","volume":"9","author":"Tamma","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2022.113787_bib47","first-page":"11","article-title":"Dendritic cells and their role in immunotherapy","author":"Gardner","year":"2020","journal-title":"Front. Immunol."},{"issue":"5904","key":"10.1016\/j.biopha.2022.113787_bib48","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1126\/science.1164206","article-title":"Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity","volume":"322","author":"Hildner","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.biopha.2022.113787_bib49","doi-asserted-by":"crossref","unstructured":"M. Binnewies, et al., Unleashing type-2 dendritic cells to drive protective antitumor CD4(+) T cell immunity, Cell, vol. 177(no. 3), 2019, p. 556\u2013+.","DOI":"10.1016\/j.cell.2019.02.005"},{"issue":"22","key":"10.1016\/j.biopha.2022.113787_bib50","doi-asserted-by":"crossref","first-page":"7466","DOI":"10.1158\/1078-0432.CCR-04-0684","article-title":"Dendritic cell infiltration and prognosis of early stage breast cancer","volume":"10","author":"Treilleux","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.biopha.2022.113787_bib51","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10549-011-1620-1","article-title":"The prognostic significance of B lymphocytes in invasive carcinoma of the breast","volume":"132","author":"Mahmoud","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"issue":"24","key":"10.1016\/j.biopha.2022.113787_bib52","doi-asserted-by":"crossref","first-page":"6125","DOI":"10.1158\/1078-0432.CCR-18-1481","article-title":"Prognostic significance of tumor-infiltrating B cells and plasma cells in human cancer","volume":"24","author":"Wouters","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"15","key":"10.1016\/j.biopha.2022.113787_bib53","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1200\/JCO.2010.30.5037","article-title":"Tumor-infiltrating CD8(+) lymphocytes predict clinical outcome in breast cancer","volume":"29","author":"Mahmoud","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.biopha.2022.113787_bib54","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41568-019-0153-5","article-title":"gammadelta T cells: pleiotropic immune effectors with therapeutic potential in cancer","volume":"19","author":"Silva-Santos","year":"2019","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.biopha.2022.113787_bib55","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41568-020-0283-9","article-title":"A new dawn for eosinophils in the tumour microenvironment","volume":"20","author":"Grisaru-Tal","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2022.113787_bib56","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/biomedicines9091087","article-title":"Immunity and breast cancer: focus on eosinophils","volume":"9","author":"Poncin","year":"2021","journal-title":"Biomedicines"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222011763?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222011763?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T11:17:36Z","timestamp":1781781456000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222011763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":56,"alternative-id":["S0753332222011763"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113787","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patterns of immune infiltration and survival in endocrine therapy-treated ER-positive breast cancer: A computational study of 1900 patients","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113787","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"113787"}}